CGEN - Compugen Ltd.
| Previous Close | 3.05 |
| Open | 3.05 |
| Bid | 2.95 x 3200 |
| Ask | 3.15 x 1100 |
| Day's Range | 3.05 - 3.15 |
| 52 Week Range | 2.25 - 5.00 |
| Volume | 74,609 |
| Avg. Volume | 205,334 |
| Market Cap | 174.451M |
| Beta | 1.50 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.55 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.67 |
- Associated Press•14 days ago
Compugen: 2Q Earnings Snapshot
The Holon, Israel-based company said it had a loss of 19 cents per share. The company's shares closed at $3.15. A year ago, they were trading at $4.05. _____ This story was generated by Automated Insights ...
- PR Newswire•14 days ago
Compugen Reports Second Quarter 2018 Results
Preparations for first patient dosing on track to take place in early fall HOLON, ISRAEL , Aug 1, 2018 /PRNewswire/ -- Compugen Ltd. ( Nasdaq: CGEN ), a clinical-stage cancer immunotherapy company and ...
- ACCESSWIRE•14 days ago
Compugen Ltd. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 1, 2018 / Compugen Ltd. (NASDAQ: CGEN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 1, 2018 at 8:30 AM Eastern Time. To listen ...
- PR Newswire•28 days ago
Compugen Second Quarter 2018 Conference Call Scheduled for Wednesday, August 1, 2018 at 8:30 AM ET
HOLON, Israel , July 18, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company ...
- Benzinga•last month
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Alkermes Plc (NASDAQ: ALKS ) stock was trading higher ...
- PR Newswire•last month
Compugen Welcomes FDA Clearance of Bayer's IND Application for BAY 1905254
HOLON, Israel, July 2, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN) (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, was informed that the U.S. Food and Drug Administration (FDA) has cleared Bayer AG's investigational new drug (IND) application for BAY 1905254, a first-in-class immuno-oncology therapeutic antibody targeting the ILDR2 protein in patients with advanced solid tumors. ILDR2 is a novel immune checkpoint discovered by Compugen through its predictive computational capabilities, which enable the discovery of new drug targets and biological pathways.
- PR Newswire•last month
Compugen Announces FDA Clearance of IND Application for COM701, a First-in-class Immuno-Oncology Therapeutic Antibody
Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on its investigational new drug (IND) application for COM701, a first-in-class immuno-oncology therapeutic antibody targeting PVRIG in patients with advanced solid tumors, and informed the Company it may initiate the clinical study. "Today is a significant milestone for Compugen, having received clearance from the FDA to advance our lead immuno-oncology program into the clinic. COM701 is a first-in-class drug opportunity that was developed by Compugen from discovery of the drug target by computer prediction through preclinical development, to IND clearance," stated Anat Cohen-Dayag, PhD, President and CEO of Compugen.
- Simply Wall St.•2 months ago
When Should You Buy Compugen Ltd (NASDAQ:CGEN)?
Compugen Ltd (NASDAQ:CGEN), a life sciences company based in Israel, saw a double-digit share price rise of over 10% in the past couple of months on the NasdaqGM. Less-covered, smallRead More...
- PR Newswire•2 months ago
Compugen Announces $21 Million Registered Direct Offering of Ordinary Shares and Warrants
Compugen Ltd. (CGEN)(CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors providing for the issuance of approximately 5.3 million of its ordinary shares at a purchase price of $3.95 per share, which represents the closing bid price on June 14, 2018, in a registered direct offering. In connection with the issuance of the ordinary shares, Compugen will also issue warrants to purchase up to approximately 4.3 million additional ordinary shares. The warrants have an exercise price of $4.74 per share, will be exercisable six-months following their issuance and will have a term of five years from the date of issuance.
- PR Newswire•2 months ago
Compugen Announces the Appointment of New Board Members
HOLON, Israel, June 11, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the appointment of three new members to its Board of Directors. Mr. Gilead Halevy, founding member and general partner of Kedma Capital Partners, Kinneret Livnat Savitzky, Ph.D., Interim CEO and board member of FutuRx Ltd., and Mr. Sanford (Sandy) Zweifach, founder and CEO of Nuvelution Pharma, Inc. were appointed to Compugen's Board.
- Zacks•3 months ago
Market Has Not Yet Noticed Potential in Compugen; Have You?
Compugen (CGEN) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.
- Associated Press•3 months ago
Compugen: 1Q Earnings Snapshot
On a per-share basis, the Holon, Israel-based company said it had profit of less than 1 cent. The drug developer posted revenue of $10 million in the period. The company's shares closed at $3.33. A year ...
- PR Newswire•3 months ago
Compugen Reports First Quarter 2018 Results
HOLON, Israel , May 9, 2018 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for ...
- Simply Wall St.•3 months ago
Compugen Ltd (NASDAQ:CGEN): Should The Recent Earnings Drop Worry You?
When Compugen Ltd (NASDAQ:CGEN) released its most recent earnings update (31 December 2017), I wanted to understand how these figures stacked up against its past performance. The two benchmarks IRead More...
- PR Newswire•4 months ago
Compugen First Quarter 2018 Conference Call Scheduled for Wednesday, May 9, 2018 at 10:00 AM ET
HOLON, Israel , April 30, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that ...
- PR Newswire•4 months ago
Compugen Reports on Status of Investigational New Drug Application for COM701, a First-in-Class Immuno-Oncology Therapeutic Antibody
HOLON, Israel, April 27, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) requested that the Company provide additional CMC information in support of its IND application for COM701, initially submitted in late March 2018. COM701 is a first-in-class immuno-oncology therapeutic antibody targeting PVRIG. FDA recommended a lower starting dose of COM701 for the trial, which now requires a more sensitive COM701 assay detection method for this dose.
- ACCESSWIRE•4 months ago
Blog Exposure - Preclinical Data Presented by Bayer at AACR Highlights Compugen’s BAY 1905254 Efficacy in Cancer Immunotherapy
LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free research report on Compugen Ltd (NASDAQ: CGEN). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CGEN as the Company's latest news hit the wire. On April 17, 2018, the Company announced that preclinical data presented by Bayer AG at the Annual Meeting of the American Association of Cancer Research (AACR) held April 14-18, 2018, in Chicago, Illinois, highlights the efficacy of BAY 1905254 (formerly the CGEN-15001T program) in cancer immunotherapy.
- PR Newswire•4 months ago
Preclinical Data Presented by Bayer at AACR Highlights BAY 1905254, Formerly the CGEN-15001T Program, Efficacy in Cancer Immunotherapy
HOLON, Israel, April 17, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that preclinical data presented by Bayer AG at the Annual Meeting of the American Association of Cancer Research held April 14-18, 2018, in Chicago, Illinois, highlights the efficacy of BAY 1905254 (formerly the CGEN-15001T program) in cancer immunotherapy. BAY 1905254 is a first-in-class therapeutic antibody candidate targeting ILDR2, a novel immune checkpoint discovered by Compugen.
- Benzinga•4 months ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! SYNNEX Corporation (NYSE: SNX ) stock lost more than ...
- PR Newswire•4 months ago
Compugen Announces Exclusive License Agreement With MedImmune for the Development of Bi-Specific and Multi-Specific Antibody Products
Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced it entered into an exclusive license agreement with MedImmune, the global biologics research and development arm of AstraZeneca, to enable the development of bi-specific and multi-specific immuno-oncology antibody products. Under the terms of the agreement, Compugen will provide an exclusive license to MedImmune for the development of bi-specific and multi-specific antibody products derived from a Compugen pipeline program.
- Reuters•4 months ago
Compugen, AstraZeneca unit in cancer drug development deal
Israeli drugmaker Compugen Ltd (CGEN.TA) (CGEN.O) said it had agreed an exclusive licensing deal with a unit of AstraZeneca (AZN.L) to develop antibody products to treat cancer, which could be worth more than $200 million (142.25 million pounds). Under the terms of the deal announced on Monday, MedImmune - the research and development arm of AstraZeneca - will develop genetically engineered antibody products derived from Compugen's oncology drug pipeline and pay royalties to the Israeli firm.
- Reuters•4 months ago
Compugen, AstraZeneca unit in cancer drug development deal
Israeli drugmaker Compugen Ltd said it had agreed an exclusive licensing deal with a unit of AstraZeneca to develop antibody products to treat cancer, which could be worth more than $200 million. Under the terms of the deal announced on Monday, MedImmune - the research and development arm of AstraZeneca - will develop genetically engineered antibody products derived from Compugen's oncology drug pipeline and pay royalties to the Israeli firm.
- Simply Wall St.•5 months ago
At $3.95, Is Compugen Ltd (NASDAQ:CGEN) A Buy?
Compugen Ltd (NASDAQ:CGEN), a life sciences company based in Israel, led the NasdaqGM gainers with a relatively large price hike in the past couple of weeks. Less-covered, small caps tendRead More...
- PR Newswire•5 months ago
Compugen Announces Appointment of Henry Adewoye, MD, as Chief Medical Officer
HOLON, Israel, March 26, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced the appointment of Dr. Henry Adewoye, to the newly created position of Chief Medical Officer, effective immediately. Dr. Adewoye brings to Compugen over two decades of extensive and broad experience in leading multiple clinical trials in oncology and hematology in both the biopharmaceutical industry and academia. As Chief Medical Officer, Dr. Adewoye will play a key role in leading the Company's transition into a clinical stage company, and will assume overall responsibility of Compugen's clinical stage pipeline programs.
